BAT8010 — Investigational Agent
Antibody-Drug Conjugate · Phase 1/2 · Bio-Thera Solutions
Mechanism of Action
An anti-HER2 antibody-drug conjugate carrying a topoisomerase I inhibitor payload, designed for targeted delivery and bystander cytotoxicity in HER2-expressing tumors; studied as monotherapy and with the anti-HER2 antibody BAT1006.
Investigational Indications
- HER2-positive breast cancer
- HER2-expressing gastric/gastrointestinal tumors
- Advanced HER2-expressing solid tumors